Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the European Respiratory Society Annual Congress 2011 in Amsterdam
(Thomson Reuters ONE) -
Revotar Biopharmaceuticals AG /
Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the
European Respiratory Society Annual Congress 2011 in Amsterdam
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
BERLIN/Hennigsdorf (Germany), September 21, 2011 - Revotar Biopharmaceuticals AG
recently announced that it successfully completed a multi-center Phase II trial
to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of
patients with chronic obstructive pulmonary disease (COPD).
Data have been accepted for the late breaking news session at the upcoming
annual congress of the European Respiratory Society (ERS) in Amsterdam and will
be presented by the research group of Prof. Helgo Magnussen in an oral
presentation Tuesday, September 27th during Session 460 (14:45-16:45, Forum).
As previously released, inhalation of Bimosiamose for 28 days on top of standard
bronchodilators was safe and well tolerated in 77 patients with moderate to
severe COPD (GOLD II-III). It led to a broad and significant attenuation of
airway inflammation and trend towards lung function improvements.
"Our data with Bimosiamose demonstrate a significant step forward in the anti-
inflammatory treatment of COPD", said Prof. Wolfgang Meyer-Sabellek, CMO of
Revotar. "We will discuss future clinical development of our first in class
inhaled drug with international key opinion leaders in Amsterdam at one of the
biggest and renowned respiratory conferences worldwide."
"We are encouraged that our data are appreciated by the scientific community as
a major milestone on the way towards the establishment of pan-selectin
antagonism as a novel therapeutic option in COPD", added Dr. Martin Pöhlchen,
CEO of Revotar.
About COPD
Chronic Obstructive Pulmonary Disease (COPD) comprises several serious
conditions affecting the lung. According to the WHO, estimated 64 million people
have COPD worldwide in 2004. More than 3 million people died of COPD in 2005,
which corresponds to 5% of all deaths globally. The WHO predicts that COPD will
become the third leading cause of death worldwide by 2030. In 2010, the global
COPD market recorded sales of approximately 11 billion US-$. There is a high
unmet medical need in drugs modifying the underlying inflammation in COPD.
About Revotar Biopharmaceutical AG
Revotar develops innovative drugs for inflammatory indications such as chronic
obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its
lead candidate Bimosiamose, a pan-selectin antagonist, has already passed
several clinical phase I and phase IIa trials in COPD, asthma, and psoriasis
with a good safety and efficacy profile in over 300 patients and volunteers.
Furthermore Revotar has two preclinical programs addressing respiratory and
other inflammatory diseases.
Contact Address:
Dr Martin Pöhlchen, CEO
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a
D-16761 Hennigsdorf / Germany
Phone: +49-3302-2025010
Fax: +49-3302-2025030
Email:info(at)revotar.com
www.revotar.com
--- End of Message ---
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a Hennigsdorf Germany
Press Release (PDF):
http://hugin.info/143207/R/1548488/475879.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE
[HUG#1548488]
Unternehmensinformation / Kurzprofil:
Datum: 21.09.2011 - 10:17 Uhr
Sprache: Deutsch
News-ID 68240
Anzahl Zeichen: 4346
contact information:
Town:
Hennigsdorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the European Respiratory Society Annual Congress 2011 in Amsterdam"
steht unter der journalistisch-redaktionellen Verantwortung von
Revotar Biopharmaceuticals AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
